$GOSS News

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $2

Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk

Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And Equity

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio (GOSS) Q1 2026 Earnings Transcript

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $5 Price Target

Gossamer Bio, Inc. 2026 Q1 - Results - Earnings Call Presentation

Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript

Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS)

Gossamer Bio Q1 Earnings Call Highlights

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript

Gossamer Bio Launches Exchange Offer For $72M New 7.5% Notes, Up To 317.6M Shares/Prefunded Warrants, Plus Early Tender Purchase Warrants

Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026